Comparison
While CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While CJC-1295 works as a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
CJC-1295 is 29 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. CJC-1295 is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Glutamine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Alanine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Leucine, Serine, Arginine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
CJC-1295
GHRH
Tirzepatide
Not assigned in the current dataset.